Pular para o conteúdo principal
Ranking Invest

BEAM - Beam Therapeutics Inc.

Segmento: HealthcareBeam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-19,02%
$ 223.36 Mi
Valor de Mercado
$ 2.48 Bi
Sobrepreço (AV)+1008.9%
IVR
0.09A companhia vale 0,09 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.35O valuation alternativo equivale a -35% do valor de mercado da companhia.
MLL
-0.35O lucro líquido dos controladores em 16 trimestres equivale a -35% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 1.07 Bi

Dívida Líquida

-$ 119.57 Mi

L4T

-$ 85.43 Mi

MM4T

-6570.45%

Indicadores Básicos

ROE

-8.00%

Índices de Previsibilidade

Receita Líquida

F0.61

Lucro

C0.47

Margem

D0.62

Índices de Tendência

Receita Líquida

D2.76

Lucro

E-3.67

Margem

E-1.96

Índices de Endividamento

DIV/PAT

-0.11

DIV/L4T

1.40

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.